FG-3246 and enzalutamide combination therapy, in biomarker unselected patients with androgen receptor pathway inhibitor (ARPI)-treated, ...
Kyntra Bio Inc. KYNB, formerly Fibrogen, shares fluctuated in Tuesday’s premarket session as the company announced data from a Phase 1b/2 study of FG-3246 in combination with enzalutamide for treating ...
SAN FRANCISCO--(BUSINESS WIRE)--FibroGen, Inc., today announced proof-of-principle for oral anemia therapy FG-4592, a hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor (PHI), in end-stage ...
FG-3246 and enzalutamide combination therapy led to a median radiographic progression free survival (rPFS) of 10.2 months in biomarker unselected patients FG-3246 demonstrated an acceptable safety ...
FG-3246 demonstrated an acceptable safety profile; adverse events consistent with those observed in other antibody drug conjugate therapies with a MMAE payload Company plans to meet with the U.S. Food ...
A randomised phase 2 study of liposomal irinotecan in combination with 5-fluorouracil/leucovorin and oxalipalatin versus nab-paclitaxel plus gemcitabine in ...
FibroGen announced data from its Phase 2a study of FG-4592 (oral anemia therapy) in patients with stage 3-4 chronic kidney disease (CKD) and anemia. This data demonstrated that its first-in-class, ...
In the first study mentioned above, FG-3019 reversed the process of fibrosis and improved lung function in a model of radiation-induced lung fibrosis. 4 This model closely mimics progressive, ...
Company plans to meet with the U.S. Food and Drug Administration (FDA) to discuss development pathway; Phase 2 initiation is anticipated in 2H 2024 SAN FRANCISCO, April 02, 2024 (GLOBE NEWSWIRE) -- ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results